Core Viewpoint - The article discusses the development of a novel biosensor platform, SNAP-FET, which enables ultra-sensitive detection of cancer biomarkers, addressing key challenges in early cancer diagnosis [2][4]. Group 1 - The SNAP-FET platform combines codon expansion and click chemistry to achieve site-specific anchoring of nanobodies, enhancing signal transduction in serum [4]. - The platform allows for the detection of endometrial cancer biomarkers at attomolar sensitivity and provides stable electronic readouts [4]. - The portable device, ENDOCARE, can perform rapid testing within 20 minutes and can be adapted to detect various biomarkers by simply replacing functionalized nanobody chips [4]. Group 2 - SNAP-FET and ENDOCARE offer a scalable framework for next-generation biochemical sensing in point-of-care settings, particularly for early diagnosis in oncology [4].